Cargando…

Immune-Omics Networks of CD27, PD1, and PDL1 in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: There are currently no effective biomarkers to select chemotherapy, immunotherapy, and radiotherapy for treating lung cancer patients. This study identified genetic networks containing major immune-checkpoint inhibitors CD27, PD1, and PDL1, and their associated prognostic genes and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Qing, Singh, Salvi, Qian, Peter R., Guo, Nancy Lan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8428355/ https://www.ncbi.nlm.nih.gov/pubmed/34503105 http://dx.doi.org/10.3390/cancers13174296

Ejemplares similares

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Immune modulation through targeting PD-1/PDL-1 signaling pathway for the treatment of osteosarcoma lung metastastasis
por: Dhupkar, Pooja M, et al.
Publicado: (2015)

Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
por: Wu, Yumin, et al.
Publicado: (2022)

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
por: Ameli, Fereshteh, et al.
Publicado: (2022)

A Multi-Omics Network of a Seven-Gene Prognostic Signature for Non-Small Cell Lung Cancer
por: Ye, Qing, et al.
Publicado: (2021)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
por: Kumar, Gaurav, et al.
Publicado: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis
por: Chang, Chih-Hao, et al.
Publicado: (2021)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
por: Stenehjem, David D, et al.
Publicado: (2018)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
por: Makuku, Rangarirai, et al.
Publicado: (2021)

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
por: Safi, Mohammed, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma
por: Rigo, Valentina, et al.
Publicado: (2017)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

B7DC/PDL2 Promotes Tumor Immunity by a PD-1–independent Mechanism
por: Liu, Xingluo, et al.
Publicado: (2003)

Mycobacteriumtuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway
por: Cao, Shuhui, et al.
Publicado: (2019)

Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro
por: Lin, Amy H., et al.
Publicado: (2017)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points
por: Świderska, Janina, et al.
Publicado: (2021)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
por: Patil, Sachin P., et al.
Publicado: (2022)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
por: Qi, Xiaoguang, et al.
Publicado: (2020)

Circulating Low Density Neutrophils Are Associated with Resistance to First Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer
por: Arasanz, Hugo, et al.
Publicado: (2022)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

circRNA-002178 act as a ceRNA to promote PDL1/PD1 expression in lung adenocarcinoma
por: Wang, JunFeng, et al.
Publicado: (2020)

New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab
por: Bylicki, Olivier, et al.
Publicado: (2018)

Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
por: Liu, Jixiang, et al.
Publicado: (2018)

Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
por: Martin‐Romano, Patricia, et al.
Publicado: (2020)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
por: Ibrahiem, Afaf T., et al.
Publicado: (2023)

Identification and Validation of a PD-L1 Binding Peptide for Determination of PDL1 Expression in Tumors
por: Caldwell, Charles, et al.
Publicado: (2017)

Smad7 Controls Immunoregulatory PDL2/1-PD1 Signaling in Intestinal Inflammation and Autoimmunity
por: Garo, Lucien P., et al.
Publicado: (2019)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Anion binding properties of a hollow PdL-cage
por: Timmer, Brian J. J., et al.
Publicado: (2021)

A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition
por: Gong, Chang, et al.
Publicado: (2017)

Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment
por: Wang, Yan-li, et al.
Publicado: (2021)

The Presence of PDL-1 on CD8+ Lymphocytes Is Linked to Survival in Neonatal Sepsis
por: Akhmaltdinova, Lyudmila L., et al.
Publicado: (2022)

Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition
por: Gu, Chang-ling, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jsgkqbp9b51afuj9sevtvm3vfm